Eating Disorders After GLP-1s? Tirzepatide for Heart Failure; Soda Taxes and BMI

Weight-loss drugs like tirzepatide (Zepbound) and semaglutide (Wegovy) may trigger eating disorders in certain patients, doctors warned. (NBC News)

In a placebo-controlled phase III trial, tirzepatide reduced the risk of heart failure outcomes by 38% for adults with obesity and heart failure with preserved ejection fraction, Eli Lilly announced.

Bayer submitted a new drug application for elinzanetant to the FDA for the treatment of moderate to severe menopause-related vasomotor symptoms with data from the phase III OASIS trials.

A case study in JAMA Internal Medicine detailed how a 62-year-old man with obesity, hypothyroidism, and type 1 diabetes developed thyrotoxicosis due to excess exogenous levothyroxine intake after rapidly losing weight on tirzepatide.

All doses of tirzepatide for weight loss and diabetes (Mounjaro) are now available, according to the FDA’s shortage list. (Reuters)

NSYNC member Lance Bass clarified that he has latent autoimmune diabetes in adults (LADA), sometimes called type 1.5 diabetes. (People)

Patients with obesity and prediabetes lost 11.2% more of their body weight after 1 year on semaglutide 2.4 mg compared with placebo. They were also more likely to revert to normoglycemia, according to the latest study in the STEP clinical program. (Lancet Diabetes & Endocrinology)

City-level taxes on sugar-sweetened beverages were associated with lower BMI in youths, a cohort study showed. (JAMA Network Open)

Compared with other antidiabetic medications, semaglutide (Ozempic) wasn’t tied to a higher risk of adverse neuropsychiatric outcomes over a 12-month period in a propensity score-matched cohort study. (eClinicalMedicine)

Postmenopausal women who had a longer reproductive lifespan had a lower prevalence of multimorbidity in a Chinese cross-sectional study. “This study highlights the growing body of evidence that links the duration of the reproductive lifespan in women with health outcomes such as cardiovascular disease and mortality,” said Stephanie Faubion, MD, MBA, medical director of the North American Menopause Society. (Menopause)

Prescriptions for semaglutide have increased, with 2.6 million prescriptions filled at retail pharmacies by December 2023; Ozempic accounted for most fills. (JAMA Health Forum)

Please enable JavaScript to view the

comments powered by Disqus.